Fusion gene and splice variant analyses in liquid biopsies of lung cancer patients.

摘要: Obtaining a biopsy of solid tumors requires invasive procedures that strongly limit patient compliance. In contrast, blood extraction is safe, can be performed at many time points during the course disease and encourages appropriate therapy modifications, potentially improving patient's clinical outcome quality life. Fusion tyrosine kinase genes anaplastic lymphoma (ALK), C-ROS oncogen 1 (ROS 1), rearranged transfection (RET) neurotrophic (NTRK1) occur in 1-5% lung adenocarcinomas constitute therapeutic targets for inhibitors. addition, MET splicing variant exon 14, has been reported 2-4% adenocarcinoma recent studies suggests targeted therapies inhibiting signaling would beneficial patients with this alteration. review, we will summarize new techniques recently developed to detect ALK, RET, ROS NTRK1 fusions 14 liquid using plasma, serum, circulating tumor cells (CTCs), platelets exosomes as starting material.